Objective. To evaluate the effectiveness of cabergoline treatment in reducing prolactin levels and tumor size in patients with microprolactinoma. Material and Methods. The study included 59 patients diagnosed with microprolactinoma who were treated with cabergoline for 12 months. Clinical and anthropometric parameters were assessed along with prolactin levels at baseline, 3, 6, and 12 months. Tumor size was evaluated via CT at 6 and 12 months. Results. Mean prolactin levels decreased from 147.5 to 5.3 ng/mL over 12 months (p<0.001). The frequency of normoprolactinemia reached 98.3%. Tumor size reduced from 5.1 mm to 1.9 mm; complete tumor regression was observed in 18.6% of patients. Conclusion. Cabergoline is highly effective in treating microprolactinoma, significantly reducing both prolactin levels and tumor volume.
Shukurov et al. (Sat,) studied this question.